Key facts
- It has raised $3.7M across 2 recorded rounds; the latest was Seed Round ($2.8M) in May 2024.
- Notable investors include David Mills, Shelley Klingler, USC Education Technology Accelerator, Zach Messler.
- General Genomics has filed 2 Form Ds with the SEC, most recently Jan 2026 ($2.8M sold to 21 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 2 rounds
- ·The complete investor list — 4 names
- ·Watchlist + deal alerts for General Genomics
Funding rounds
2 roundsAbout General Genomics
Operator of an artificial intelligence (AI) and bioinformatics services business intended to support data-driven decision making across public sector and commercial domains. The company offers AI and machine learning-driven analytics, synthetic and de-identified data capabilities, and workflow automation tools, enabling government agencies, researchers, healthcare organizations, and commercial enterprises to extract reliable insights from complex biological and operational data with improved trust, compliance, and efficiency.
- Sector
- Business Products and Services (B2B)
- HQ
- Oklahoma City, OK, United States
- Founded
- 2020
- Employees
- 16
- Website
- ggenomics.com/
- Ownership
- Privately Held (backing)
General Genomics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in General Genomics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on General Genomics in its N-PORT filings yet. We sweep new filings monthly.